Multiple sclerosis (MS) is a neuro-inflammatory disease for which the pathogenesis remains largely unclear. Lysophosphatidic acid (LPA) is an endogenous phospholipid that is involved in multiple immune cell functions and is dysregulated in MS. Its receptor LPA1 is expressed in macrophages and regulates their activation, which is of interest due to the role of macrophage activation in MS in both destruction and repair.
Introduction
Multiple sclerosis (MS) stands out as one of the most widespread neurological diseases in young adults affecting approximately 2.3 million people worldwide (40) . MS pathogenesis consists of inflammation of the central nervous system (CNS), oligodendrocyte death and myelin damage, and many different immune cells play an important role. Although T cells have always been considered central in MS pathogenesis, new insights have unveiled the key importance of macrophages in this disease. Macrophages can play a dual role in MS pathology; they can contribute to tissue damage and inflammation, but also exert a neuroprotective and regenerative effect (30) . Their pleiotropic mode of action relies on their capacity to endorse different status of activation: classically activated, or M1, macrophages showing proinflammatory characteristics; and alternatively activated, or M2, macrophages displaying a more anti-inflammatory phenotype (46) . Each activation state plays a different role along the process of remyelination. "M1" macrophages will be the first actor of the initiation of myelin repair:
phagocytizing myelin debris and inducing oligodendrocytes precursor cells (OPC) proliferation and migration to the lesion site. Next, a switch in the macrophage population from the M1 to the M2 phenotype induces the secretion of trophic factors that foster OPC differentiation into new myelin-forming oligodendrocytes (31) . However, to what extent macrophages intrinsically contribute to myelin destruction and repair in MS remains unclear.
Lysophosphatidic acid (LPA) is a bioactive phospholipid that influences numerous cell responses, including cell motility, neuropathic pain, inflammation, fibrosis, and cancer (20, 29, 44) . The versatility of the LPA responses relies on its broad and dynamic presence in different tissues and fluids (2) , as well as on its multiple receptors, both membrane (named from LPA1 to LPA6) (48) and nuclear (the peroxisome proliferator-activated receptor γ, PPAR-γ) (27) . The expression of the LPA receptors being modular (37, 41) , contributes to the adaptability of the LPA signaling.
In the past years, the role of LPA in the pathogenesis of different immune-related diseases has been recognized. LPA dysregulation has been implicated in different inflammatory diseases, such as atherosclerosis (8) , cancer (45) , and MS (41) because of its effect on immune cells, of both the innate and adaptive immune systems (3, 15, 23) . However, despite the growing knowledge in this field, many aspects of the role of LPA in immune-related pathogenesis remain unclear. Interestingly, LPA1the first receptor of LPA to be discovered (18)has a notable importance in the physiology and pathology of the CNS (49) . While the importance of LPA in MS pathogenesis has not been neglected (4, 21, 41) , showing a dysregulation of the serum LPA levels in MS patients (4, 41) , with increased levels at relapse-onset and a role of LPA2 in T cells homing (41) , the role of LPA1 remains unclear.
LPA has been shown to induce various effects in macrophages, and it constitutes a major serum survival factor for murine macrophages (22) . Moreover, Lee et al. (23) showed that stimulation of mouse macrophages with LPA upregulated their expression of pro-inflammatory cytokines such as IL-1 and TNF-α transcripts and protein, and downregulated transcription of the anti-inflammatory IL-2. Interestingly, peripheral blood monocytes and/or tissue macrophages in both mice and humans express LPA1 receptor (1, 19) . This receptor induces their activation, migration and infiltration in different disease mouse models (32, 42) . The dysregulation of LPA and the importance of macrophage activation in MS thus present LPA1 as a potential receptor of interest in MS research.
In this work, we aim to elucidate the role of LPA1 in MS pathology, by analyzing the evolution of EAE disease course in maLPA1-null mice and in wild type mice in presence or absence of LPA1 antagonist. We provide evidence of a milder symptomatology in absence or antagonism of LPA1 receptor, suggesting a role of this receptor in the pathogenesis of the disease. This role was further strengthened with the analysis of LPA1 expression levels in peripheral blood mononuclear cells (PBMCs) from EAE mice and from patients with relapsing-remitting (RR-) MS, primary progressive (PP-) MS or secondary progressive (SP-) MS. We demonstrated that the initiation of relapses is accompanied by an increase of mouse LPA1 transcripts (Lpar1) in PBMCs. Finally, we provide in vitro data demonstrating that pro-inflammatory activation of human monocyte-derived macrophages includes increased expression of human LPA1 transcripts (LPAR1) and that LPA is involved in LPA1-driven polarization of human macrophages towards a M1-like phenotype. These results evidence a role of LPA in the initiation of the inflammatory process during MS relapses via LPA1.
In short, our studies unveil a novel mechanism for LPA in the classical activation of macrophages through LPA1, and suggest for the first time that targeting LPA1 receptors represents a promising therapeutic strategy in MS as well as for other immune-related diseases. (10) or immunohistochemistry (12) . Female maLPA1-null and wild-type mice were bred and housed in pathogen-free conditions at constant temperature (22 ± 1°C) and relative humidity (50%) under a regular light-dark schedule (light 7 am-7 pm). Food and water were freely available.
Material and Methods

Mice
Induction of EAE.
Seven-week-old female mice were immunized according to a standard protocol (28) 
LPA1 antagonist administration.
VPC 32183 (S), (S)-Phosphoric acid mono-(2-octadec-9-enoylamino-3-[4-(pyridine-2ylmethoxy)-phenyl]-propyl) ester (Ammonium Salt) (857340; Avanti Polar Lipids, Alabaster, Alabama, USA) was dissolved in 3% free-fatty acid BSA (FFA-BSA; Sigma-Aldrich) in saline.
VPC32183 was diluted to a concentration of 5 µM and 100 µl were injected intravenous in the tail vein at the time-points described in the text. In non-treated control mice only vehicle injections were performed (3% FFA BSA in saline).
Clinical evaluation.
The mice were scored four times per week as follows: limp tail or waddling gait with tail tonicity, defined score 1; waddling gait with limp tail (ataxia) as score 2; ataxia with partial limb paralysis as score 2.5; full paralysis of one limb as score 3; full paralysis of one limb with partial paralysis of second limb as score 3.5. Animals that maintained a score of at least 3.5 more than 3 days were euthanized.
Subjects
The samples for the RNA analysis of total PBMC were provided by the Biobank of our hospital, 
Isolation of PBMC for RNA extraction
PBMCs were isolated from whole blood by standard Ficoll®-Paque density gradient centrifugation. Briefly, heparinized blood was diluted with saline solution (1:1 dilution). Then, Ficoll®-Paque was covered with a layer of diluted blood. After 30 min of centrifugation (2000 rpm, room temperature (RT), without break), the PBMCs could easily be collected. After two washing steps and counting, cell were resuspended in 1 ml of Trizol® to extract RNA.
Isolation of brain infiltrating mononuclear cells for RNA extraction
Infiltrated mononuclear cells (IMNCs) were isolated from CNS of EAE mice using the following procedure (6) . After dissecting brain and spinal cord from individual animals, these were minced finely in phosphate buffer saline, centrifuged and resuspended in 37% Percoll®. This suspension was layed on a 70% Percoll® cushion and spun at 600 x g at room temperature for 25min. CNS IMNCs were obtained from the 37-70% Percoll® interface, washed twice, and cell counted. Finally, cells were resuspended in 1 ml of TRIzol® for RNA extraction. acatccagcaataacaagaccaatc, Gapdh forward: gccaaggtcatccatgacaact, and reverse: gaggggccatccacagtctt). A melting curve analysis was performed to assess primer specificity and product quality by step-wise denaturation of the PCR product at a rate of 0.1°C/sec to 98°C.
RT-PCR of PBMC and IMNC
The relative levels of receptor expression were quantified using the standard curve method.
Isolation of Primary Monocytes and macrophage culture and activation.
Blood was sampled from all participants in acid citrate dextrose (ACD) tubes. From blood samples, peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll Paque Plus (GE Healthcare Life Sciences) and centrifugation (2200 rpm, 20 min without brake). Cells were washed in PBS (2x10 min at 1500 rpm) and RPMI 1640 + 10% fetal bovine serum (FBS) (5 min at 1500 rpm) (all products from ThermoFisher). Monocytes were isolated with anti-CD14 microbeads (Miltenyi) and plated in 12-well plates (500 000 cells/well) or in 24-well plates (200 000 cells/well) in RPMI 1640 + 10% FBS and granulocyte macrophage colony-stimulating factor (GM-CSF) (500 U/ml, ImmunoTools). After 72h, media was replaced with fresh media and one of the following: GM-CSF (500 U/ml); IFNβ (100 U/ml, ImmunoTools); IL-4 (1000 U/ml, ImmunoTools); or combined IFNγ (200 U/ml, ImmunoTools) and ultra-pure LPS (10 ng/ml, InvivoGen). Cell lysis and RNA extraction were performed 24h post-activation using Nucleospin RNA extraction kit (Macherey-Nagel). Quality of RNA was confirmed on Agilent TapeStation (RINe>8).
For LPA treatment and antagonist, LPA (Tocris, 3854) and Ki16425 (Sigma, SML0971) were dissolved in 3% BSA to add to the medium at a final concentration of 1µM LPA and 400nM
Ki16425 during 24h.
RNA sequencing
Transcriptome sequencing cDNA libraries of macrophage RNA were prepared using a stranded mRNA polyA selection (Truseq stranded mRNA kit, Illumina). For each sample, we performed 60 million single-end, 75 base reads on a NextSeq 500 sequencer (Illumina). RNA-Seq data analyses were performed by GenoSplice technology (www.genosplice.com). Sequencing, data quality, reads repartition (e.g., for potential ribosomal contamination), and insert size estimation were performed using FastQC, Picard-Tools, Samtools and rseqc. Reads were mapped using STARv2.4.0 (11) on the hg19 Human genome assembly. Gene expression regulation study was performed as previously described (34) . Briefly, for each gene present in the FAST DB v2018_1 annotations, reads aligning on constitutive regions (that are not prone to alternative splicing) were counted. Based on these read counts, normalization was performed using DESeq2 (26) 
RT-PCR of monocyte-derived macrophages
Results
LPA1 deletion leads to milder EAE clinical course.
Recently, a role of LPA in the pathogenesis of the MS and its animal model, EAE, has been suggested (41), focusing on the contribution of LPA2-expressing T cells. Here, we question whether LPA1, another LPA receptor, also present in immune cells, could have a role in EAE.
To answer this question, we first compared the EAE clinical course in presence and absence of LPA1 by comparing MOG35-55 induced-EAE in wild type and in the Malaga variant of LPA1-null mouse line (maLPA1-null mouse) (12) .
Analysis of their clinical courses showed a relapsing-remitting clinical course in both wild-type and LPA1-null animals but also highlighted also important differences between the two genotypes. Notably, maLPA1-null mice showed a less severe clinical course compared to wildtype mice (Fig. 1A) , measured as the area under the curve (AUC). In addition, maLPA1-null mice exhibited a significantly lower average clinical score and maximal clinical score reached during relapses as well as a better recovery during remission ( Fig.1B) .
Intravenous injection of an LPA1 antagonist ameliorates EAE clinical score in wild-type mice.
LPA1 is also expressed in oligodendrocytes and we previously demonstrated that its absence perturbs developmental myelination in maLPA1-null mice (14) . To exclude any interference of deficient myelin patterns in the EAE outcome in LPA1-null animals, we used a pharmacological approach in wild-type mice, intravenously injecting an LPA1 antagonist (VPC32183) that primarily blocks LPA1 (10-100nM range), and partially blocks LPA3 (10-fold lower; 100-1000nM range) (17) .
We first administered a single dose of the antagonist at the clinical onset of the disease, at 14 days post-immunization (dpi). This protocol resulted in a trend towards an amelioration during the first 5 days ( Fig. 2A ). However, after that period, the symptoms reappeared more severely.
Due to its lipidic structure, LPA1 antagonist could easily be metabolized in the blood stream, explaining the short duration of its positive effects.
To maintain the levels of the antagonist, new sets of immunized mice were treated with repeated doses of VPC32183 every 5 days ( 
Lpar1 expression increases when mononuclear cells invade the CNS
Under normal physiological conditions, mononuclear cells are rarely found in the CNS.
However, in MS and EAE, activated immune cells infiltrate the CNS. Due to the reported role of LPA1 in immune cells infiltration (42) , and its obvious impact in the clinical course, we analyzed whether the number of infiltrating mononuclear cells (IMNC) was altered in EAE-mice lacking LPA1. We quantified the number of IMNCs isolated by Percoll gradient (6) from brain and spinal cord of wild type and maLPA1-null mice with similar clinical score. We did not find significant differences in the number of infiltrates ( Fig. 3A ), suggesting that LPA1 modulation of EAE course might intervene at another step of immune cell activation beside infiltration.
Despite LPA1 not being essential for infiltration, its expression still appeared to be related to the EAE pathogenesis. Thus, we analyzed the Lpar1 expression in circulating immune cells (PBMCs) and CNS-IMNCs from wild-type mice using RT-PCR and our results show an increase of Lpar1 expression after immune cell infiltration in the CNS compared to PBMCs (Fig. 3B) .
These data suggest that an increase of Lpar1 expression reflects immune cell activation.
Onset of EAE relapses correlates with increase expression of Lpar1 in PBMCs.
Knowing that Lpar1 is expressed by immune cells, and that immune cells are critical for EAE development, we wondered whether Lpar1 expression in PBMCs reflects disease activity. To this end, the expression of Lpar1 in PBMCs along the EAE clinical course was evaluated in wild-type mice.
MOG-immunized animals showed a two-fold significant increase of Lpar1 expression compared to control animals (Fig. 4A ). However, no significant correlation was found between Lpar1 expression and clinical score after sacrifice (EAE score 1: 0,459818 ± 0,123361 (n=9); EAE score 2: 0,681039 ± 0,151682 (n=7); EAE score 3: 0,648933 ± 0,144792 (n=8)).
To decipher whether Lpar1 expression in PBMCs might reflect a different phase of the disease, Lpar1 expression was analyzed according to mice stratification based on whether animals were initiating a relapse or in remission/progressive course of the disease at the moment of the sampling. There was a significantly increased expression of Lpar1 during relapses when compared to control animals or animals in remission or progressive episodes ( Fig. 4B ). Of note, Lpar1 expression and clinical symptoms of EAE were significantly positively correlated during the clinical course of the disease (Fig. 4C ).
LPAR1 expression increases during relapses in RRMS patient PBMCs.
Our previous observations in EAE mice suggested a modulation of LPA1 in the first stages of Like in EAE, LPAR1 expression was significantly higher in RR-MS patient PBMCs than in healthy subjects or progressive patients (Fig. 5B ). Thus, we provide evidence that alterations in LPAR1 expression associates with the inflammatory phase of MS.
LPAR1 expression correlates with a pro-inflammatory phenotype of human monocytederived macrophages
Circulating PBMCs are mainly composed of lymphocytes and monocytes. We decided to focus on monocytes/macrophages because of their dual role in MS pathology (46) , being both deleterious when endorsing a pro-inflammatory phenotype and beneficial under proregenerative activation (30, 31) .
To elucidate the role of LPA1 in macrophages polarization, we obtained naïve circulating monocytes from RR-MS patients in remission. Naïve monocytes remain circulating in the blood stream for a short period before infiltrating the tissues (38) , reducing the impact of other circulating factors before blood extraction. Blood CD14+ monocytes were differentiated into macrophages in vitro using GMCSF before testing the role of LPA in macrophage polarization.
In order to elucidate how LPA1 might correlate the macrophage activation state, monocytederived macrophages from healthy controls (Fig 6, circles) or MS patients (Fig 6, triangle) were directed toward a pro inflammatory (LPS+IFNɣ, Fig 6, blue) , a pro regenerative state (IFNβ (Fig   6, purple) or IL-4 (Fig 6, red) ) or a neutral state (GMCSF, Fig 6 green) . We next evaluated by RNA sequencing, the expression of three LPA receptors: two membrane receptors, LPA1 and LPA2, and a nuclear receptor PPAR.
Interestingly, these receptors were differentially regulated, while we could not detect a difference of LPAR2 expression ( Fig. 6A ) in any activation state, we observed an inverse pattern of expression for LPAR1 ( Fig 6B) and PPAR (Fig. 6C) 
LPA mediates human macrophage polarization.
In addition to the increase of LPA1 in pro-inflammatory macrophages (Fig. 6B ), LPA levels are altered along the course of MS (4, 41) suggesting an important role of this phospholipid in the course of the disease. We therefore tested whether LPA could promote an M1-phenotype in macrophages, as has been observed in murine microglia (39) .
We examined transcripts specific for pro-inflammatory or pro-regenerative profiles to test the effect of LPA treatment for 24h, and compared the expression of different markers with the canonical M1 polarization by LPS (Fig. 7) .
The levels of different M1 markers (CCL2, CCL20, CCL5, CD68 and TLR2), though to a lesser extent after LPS treatment, increased after LPA incubation, indicating a role of LPA in the proinflammatory activation of human macrophages. Moreover, this polarization was partially inhibited by addition of an LPA1 inhibitor (Ki16425) revealing the mediation of LPA1 in this LPA response ( Fig. 7) . No significant alterations in the expression of M2 markers were observed after LPA incubation.
Discussion
In this study, we present evidence of a role of a receptor of LPA (a signaling molecule with a broad effector profile (9) and described roles in inflammation (48)) in the pathogenesis of the neuro-inflammatory disease MS and its animal model, EAE. We also propose a mechanism through which LPA may exert this effect via macrophage activation.
After the discovery of the first receptor for LPA, the LPA1, in 1996 (18) , this receptor has been implicated in a numerous process, with an outstanding importance in the physiology and pathology of the CNS (49) . In this context, the importance of LPA in MS pathogenesis, one of the broadest spread neuro-inflammatory diseases has been suggested (4, 21, 41) . However, the role of LPA1 in the MS pathogenesis remains unclear. In the present study, we unveil a new aspect of LPA through the LPA1 receptor in this neuro-inflammatory disease.
Our results show for the first time, the importance of the receptor LPA1 in EAE clinical course.
The lack of LPA1, or its pharmacological inhibition by the repetitive intravenous injections of a LPA1 antagonist (VPC32183), reduces the severity of the disease as seen by a lower average clinical score and lower maximal score during relapses as well as better recovery during remission. The milder symptoms in the absence of LPA1 signaling indicates that this pathway is involved in EAE pathogenesis. This is in contrast with a study of another LPA receptor, LPA2, of which reduction led to more severe disease (41) . This indicates a complex role of LPA in MS and EAE, and that potential treatment strategies should target specific pathways rather than LPA as a whole.
Previous studies have described a role for LPA and autotaxin, its main synthetic enzyme, in inflammatory processes (8, 25, 43, 45) . In line with this, we found that expression of LPA1 was To understand how LPA1 exerts its influence on the inflammatory component of MS and EAE, we examined infiltration and activation of immune cells. In the case of LPA2, its effect on the EAE disease course appears to be reliant on its capacity to increase T-cell homing, thus reducing infiltration. While studies have indicated a detrimental role of LPA1 in blood-brainbarrier (BBB) integrity (5, 36, 47) and potential to increase extravasation through induction of chemokine expression (24), our results did not indicate a significant impact of LPA1 deletion on infiltration of PBMCs into the CNS. While this does not exclude an effect below statistical significance or an effect of BBB leakage independent of PBMC infiltration, we cannot explain the amelioration of clinical scores through reduced infiltration. Instead, the observation that infiltrating cells express Lpar1 to a higher degree than peripheral cells in EAE wild-type mice suggests that LPA1 is involved in immune cell activation without necessarily affecting infiltration.
Following the hypothesis that LPA1 correlates with immune cell activation, we examined its expression in activated human macrophages. Our results show an increase of LPAR1 expression, but not LPAR2, in both healthy control and RR-MS patient macrophages when activated towards a pro-inflammatory phenotype. On the other hand, expression of the LPA nuclear receptor PPAR not only decreases when macrophages acquire M1 polarization but also shows a trend towards increasing after pro-regenerative activation. We did not identify a difference between MS patients and healthy controls, but this could be due to the fact that MS samples were taken during a remission phase. In this case, the modular expression of different LPA receptors after differential activation hints a complex role of LPA signaling in the homeostasis of macrophages during the disease and suggests that modulating the expression or saturating the activation of one or the other one could be a mechanism of trans-differentiation of human macrophages. Although this aspect requires further study, the fact that LPA1 is related to glycolysis (7, 16, 33) (main source of energy for pro-inflammatory polarized macrophages) and PPARƔ induces oxidative phosphorylation (35) , and that these two metabolic processes are central in pro-and anti-inflammatory macrophage activation respectively (13) , suggests that the modulation of these LPA receptors could have major implications in the macrophage physiology and activation.
Knowing that LPA is dysregulated in MS relapses (4, 21) and that LPAR1 expression is increased in macrophage activation, we hypothesized that LPA1 could mediate LPA-induced pro-inflammatory activation in macrophages. This was confirmed through increased expression of M1 markers following LPA incubation with partial correction by exposure to the LPA1 antagonist Ki16425. Increased expression of LPA1 in EAE and MS PBMCs during relapse thus suggests both an activated state as well as a predisposition to further pro-inflammatory activation. The coordinated responses between the induced-LPA1 expression and the proinflammatory activation of LPA via the LPA1 will promote a positive feedback loop that grants to LPA the role of boosting the inflammatory response and maintain the classical activation of macrophages. The milder EAE clinical course observed in LPA1-null and LPA1-antagonized mice, which present lower maximal and minimal scores in relapses and remissions respectively, could therefore be explained with a milder activation of immune cells, whereas the number or relapses and the onset of the disease unaffected as infiltration still occurs to the same extent.
In short, our study unveils for the first time a role of the LPA1 in the pathogenesis of MS and its animal model, EAE, and the importance of the regulation of the LPA signaling in the development of the disease. In addition to opening up new avenues for immuno-modulatory treatment, this research also indicates a potential for LPA1 as a biomarker of disease activity.
Further research on LPA in MS should therefore consider the exact pathways being targeted and the current level of disease activity in the patient, in order to develop strategies to better follow and treat these neurological patients.
Fig. 1. LPA1 null mice exhibit a less severe EAE disease course than wild type (WT).
A) EAE disease progression in wild-type (n=14) and maLPA1 knockout (n=20) mice. Graphs present mean values with error bars indicating + SEM of summarizes data from three independent experiments. Statistical significance was assessed by Mann-Whitney test of AUC (p=0.027) B) Comparison of clinical parameters of EAE in wild-type and maLPA1 null mice. Tstudent test for the average clinical score p=0.01; for the max score p=0.03; and for the min score p=0.04. * means p<0.05. RNA sequencing analysis. Comparison of macrophage expression profiles in naïve (GMCSF), classically activated (LPS+INFg) or alternatively (IFNβ or IL4) human macrophages, from HD (n=9) and RR-MS patients (n=22). While LPAR2 expression did not change after any type of activation (A), LPAR1 expression was significantly increased in both HD and RR-MS patients after pro inflammatory activation (B). In contrast, the nuclear LPA receptor PPARɣ was increased in the pro-regenerative state and significantly reduced in pro inflammatory macrophages in HD but not in RR-MS patients (C). 
